Sensorion and Cochlear Announce Collaboration to Study Combination Therapies for Cochlear Implant Patients. Read

2017 First-half results

Read

Sensorion’s Oral SENS-401 Prevented Cisplatin-Induced Hearing Loss By More than 50 Percent in Preclinical Study

pdfRead

Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients

Read

Sensorion Amends Existing Convertible Notes Program Under More Favorable Terms with €10 Million in Financing

Read

Pipeline

20190603 pipeline

Enregistrer

Patient center

Corporate presentation

Next events